Please login to the form below
Ranbaxy wins FDA approval for Metformin in US
India-based Ranbaxy Laboratories' 100 per cent-owned Ohm Laboratories has won FDA approval to manufacture and market Metformin tablets in the US.
India-based Ranbaxy Laboratories' 100 per cent-owned Ohm Laboratories has won FDA approval to manufacture and market Metformin tablets in the US.
Ipca Laboratories, which has a strategic alliance with Ranbaxy, will manufacture the formulation at its facilities in India. Ranbaxy will commercialise the product in the US market, Ipca revealed in a press statement to the Bombay Stock Exchange.
Total annual US sales for Metformin, an insulin sensitising agent, was USD 379m, according to Ranbaxy.
Share
Related Hub content
Featured jobs
- Account Director, Healthcare Communications
-
Salary TBC
-
Senior External Communications Lead
-
£Competitive Salary
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
-
Scientific Director
-
£60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more
-
Experienced medical editor
-
Competitive salary and bonus scheme
-
Account Manager
-
£Competitive Salary
-
Account Director
-
£Competitive Salary
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Digital Associate Director - Medcomms
-
£65000 - £80000 per annum
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account Director, Medical Education
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Account director
-
Competitive salary and bonus scheme
-
Account Manager (PR)
-
Great Benefits
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
-
Publications director
-
Competitive salary and bonus scheme
Subscribe to our email news alerts
- US backs Sanofi’s ‘fast-track’ coronavirus vaccine
- AbbVie/Allergan merger faces renewed public opposition despite divestments
- Genital herpes vaccine candidate heads for human studies
- As new coronavirus outbreaks emerge, fears of a global pandemic escalate
- FDA sets June decision date for Tecentriq monotherapy in NSCLC
- Merck’s Ebola vaccine wins approval in four African countries
- Introducing Nucleus POLAR™, a state-of-the-art external expert search engine and engagement management tool
- Moderna and GSK advance coronavirus vaccine candidates
- FDA accepts review to broaden GSK’s Zejula label
- Sanofi says it will spin out active ingredient business by 2022
- Coronavirus outbreak escalation could impact drug supply chain
- Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA
PMHub
GCI Health
GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...
Latest intelligence
- BRIC markets
- Why these countries offer an opportunity for pharma despite a slowdown...
- Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
- Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
- Novo Nordisk awakens its ‘Sleeping Beauty’
- Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
Quick links
Infographics
